CLAIM EXHIBITS

- A. An isolated peptide capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being:
- (A) a core peptide identical to positions 89-96 of the sequence of human C-reactive protein (CRP) of the formula:

Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3);

- (B) a modification of (A) in which one or more of the following additional modifications is optionally made:
 - (i) substitution of Ile_{96} by a hydrophobic amino acid residue;
 - (ii) substitution of His₉₅ by Asp, Glu, Ser, Thr, Phe, or Tyr, an N-alkyl derivative of His, Asp, Glu, Ser, Thr, Phe or Tyr, or a D-form of His, Asp, Glu, Ser, Thr, Phe or Tyr;
 - (iii) substitution of Val₉₄ by Ala, His or Phe, or a D-form of Val, Ala, His or Phe;
 - (iv) substitution of Ala₉₂ by a hydrophobic amino acid residue;
 - (v) substitution of Val₉₁ by Ala or Gly;
 - (vi) substitution of Thr_{90} by Asn, Asp, Gln, Glu, Ala, Val or Pro; and
 - (vii) substitution of Val₈₉ by a hydrophobic amino acid residue;

with the proviso that the residue at 89 is not Leu; (C) a peptide obtained by elongation of (A) or (B) at the N- and/or C-terminal, but not including the entire CRP; or (D) an amide of the C-terminal of (A), (B), or (C), and/or an N-acyl derivative of (A), (B), or (C). An isolated peptide capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being: a core peptide identical to positions 89-96 of (A) the sequence of human C-reactive protein (CRP) of the formula: Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3); a modification of (A) in which one or more of the following additional modifications is optionally made: (i) substitution of Ile₉₆ by a hydrophobic amino acid residue; (ii) substitution of His95 by Asp, Glu, Ser, Thr, Phe, or Tyr, an N-alkyl derivative of His, Asp, Glu, Ser, Thr, Phe or Tyr, or a D-form of His, Asp, Glu, Ser, Thr, Phe or Tyr; (iii) substitution of Val₉₄ by Ala, His or Phe, or a D-form of Val, Ala, His or Phe; (iv) substitution of Alag2 by a hydrophobic amino acid residue; (v) substitution of Val₉₁ by Ala or Gly; - 2 -

(vi) substitution of Throo by Asn, Asp, Gln, Glu, Ala, Val or Pro; and (vii) substitution of Val₈₉ by a hydrophobic amino acid residue; with the proviso that the residue at 90 is not Glu; (C) a peptide obtained by elongation of (A) or (B) at the N- and/or C-terminal, but not including the entire CRP; or (D) an amide of the C-terminal of (A), (B), or (C), and/or an N-acyl derivative of (A), (B), or (C). An isolated peptide capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being: a core peptide identical to positions 89-96 of the sequence of human C-reactive protein (CRP) of the formula: Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3); a modification of (A) in which one or more of the following additional modifications is optionally made: (i) substitution of Ile96 by a hydrophobic amino acid residue; (ii) substitution of His₉₅ by Asp, Glu, Ser, Thr, Phe, or Tyr, an N-alkyl derivative of His, Asp, Glu, Ser, Thr, Phe or Tyr, or a D-form of His, Asp, Glu, Ser, Thr, Phe or Tyr; - 3 -

(iii) substitution of Val₉₄ by Ala, His or Phe, or a D-form of Val, Ala, His or Phe; (iv) substitution of Alage by a hydrophobic amino acid residue; (v) substitution of Val₉₁ by Ala or Gly; (vi) substitution of Thr₉₀ by Asn, Asp, Gln, Glu, Ala, Val or Pro; and (vii) substitution of Val89 by a hydrophobic amino acid residue; with the proviso that the residue at 91 is not Ala; (C) a peptide obtained by elongation of (A) or (B) at the N- and/or C-terminal, but not including the entire CRP; or (D) an amide of the C-terminal of (A), (B), or (C), and/or an N-acyl derivative of (A), (B), or (C). An isolated peptide capable of inhibiting invitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being: (A) a core peptide identical to positions 89-96 of the sequence of human C-reactive protein (CRP) of the formula: Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3); a modification of (A) in which one or more of the following additional modifications is optionally made: (i) substitution of Ile₉₆ by a hydrophobic amino acid residue; - 4 -

(ii) substitution of His95 by Asp, Glu, Ser, Thr, Phe, or Tyr, an N-alkyl derivative of His, Asp, Glu, Ser, Thr, Phe or Tyr, or a D-form of His, Asp, Glu, Ser, Thr, Phe or Tyr; (iii) substitution of Val₉₄ by Ala, His or Phe, or a D-form of Val, Ala, His or Phe; (iv) substitution of Alag2 by a hydrophobic amino acid residue; (v) substitution of Val₉₁ by Ala or Gly; (vi) substitution of Thr₉₀ by Asn, Asp, Gln, Glu, Ala, Val or Pro; and (vii) substitution of Val₈₉ by a hydrophobic amino acid residue; with the proviso that the residue at 92 is not Ile; (C) a peptide obtained by elongation of (A) or (B) at the N- and/or C-terminal, but not including the entire CRP; or (D) an amide of the C-terminal of (A), (B), or (C), and/or an N-acyl derivative of (A), (B), or (C). An isolated peptide capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being: a core peptide identical to positions 89-96 of the sequence of human C-reactive protein (CRP) of the formula: Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3); - 5 -

a modification of (A) in which one or more of the following additional modifications is optionally made: (i) substitution of Ile₉₆ by a hydrophobic amino acid residue; (ii) substitution of His95 by Asp, Glu, Ser, Thr, Phe, or Tyr, an N-alkyl derivative of His, Asp, Glu, Ser, Thr, Phe or Tyr, or a D-form of His, Asp, Glu, Ser, Thr, Phe or Tyr; (iii) substitution of Val94 by Ala, His or Phe, or a D-form of Val, Ala, His or Phe; (iv) substitution of Alag2 by a hydrophobic amino acid residue; (v) substitution of Val₉₁ by Ala or Gly; (vi) substitution of Thr₉₀ by Asn, Asp, Gln, Glu, Ala, Val or Pro; and (vii) substitution of Val₈₉ by a hydrophobic amino acid residue; with the proviso that the residue at 94 is not Val; (C) a peptide obtained by elongation of (A) or (B) at the N- and/or C-terminal, but not including the entire CRP; or (D) an amide of the C-terminal of (A), (B), or (C), and/or an N-acyl derivative of (A), (B), or (C). - 6 -

An isolated peptide capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being: (A) a core peptide identical to positions 89-96 of the sequence of human C-reactive protein (CRP) of the formula: Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3); a modification of (A) in which one or more of (B) the following additional modifications is optionally made: (i) substitution of Ile96 by a hydrophobic amino acid residue; (ii) substitution of His95 by Asp, Glu, Ser, Thr, Phe, or Tyr, an N-alkyl derivative of His, Asp, Glu, Ser, Thr, Phe or Tyr, or a D-form of His, Asp, Glu, Ser, Thr, Phe or Tyr; (iii) substitution of Val94 by Ala, His or Phe, or a D-form of Val, Ala, His or Phe; (iv) substitution of Alag2 by a hydrophobic amino acid residue; (v) substitution of Val₉₁ by Ala or Gly; (vi) substitution of Thr90 by Asn, Asp, Gln, Glu, Ala, Val or Pro; and (vii) substitution of Val₈₉ by a hydrophobic amino acid residue; with the proviso that the residue at 95 is not Ser;

(C) a peptide obtained by elongation of (A) or (B) at the N- and/or C-terminal, but not including the entire CRP; or (D) an amide of the C-terminal of (A), (B), or (C), and/or an N-acyl derivative of (A), (B), or (C). An isolated peptide capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being: a core peptide identical to positions 89-96 of the sequence of human C-reactive protein (CRP) of the formula: Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3); a modification of (A) in which one or more of the following additional modifications is optionally made: (i) substitution of Ile₉₆ by a hydrophobic amino acid residue; (ii) substitution of His95 by Asp, Glu, Ser, Thr, Phe, or Tyr, an N-alkyl derivative of His, Asp, Glu, Ser, Thr, Phe or Tyr, or a D-form of His, Asp, Glu, Ser, Thr, Phe or Tyr; (iii) substitution of Val₉₄ by Ala, His or Phe, or a D-form of Val, Ala, His or Phe; (iv) substitution of Alag2 by a hydrophobic amino acid residue; (v) substitution of Val₉₁ by Ala or Gly; - 8 -

(vi) substitution of Thr₉₀ by Asn, Asp, Gln, Glu, Ala, Val or Pro; and (vii) substitution of Val₈₉ by a hydrophobic amino acid residue; with the proviso that the residue at 96 is not Ile; (C) a peptide obtained by elongation of (A) or (B) at the N- and/or C-terminal, but not including the entire CRP; or (D) an amide of the C-terminal of (A), (B), or (C), and/or an N-acyl derivative of (A), (B), or (C). - 9 -